Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03144999 | Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59 | PHASE1 | COMPLETED | 17 | — | — | Mar 29, 2017 | Dec 9, 2019 | Mar 30, 2025 | 1 | United States |
Measure intraocular inflammation, ocular changes and systemic side effects following a single intraocular injection of AAVCAGsCD59
| Arm | Type | Description |
|---|---|---|
| Low Dose | EXPERIMENTAL | AAVCAGsCD59 |
| Mid Dose | EXPERIMENTAL | AAVCAGsCD59 |
| High Dose | EXPERIMENTAL | AAVCAGsCD59 |
| Name | Type | Description |
|---|---|---|
| AAVCAGsCD59 | BIOLOGICAL | AAVCAGsCD59 is administered as a single intravitreal injection in an office setting |
Inclusion Criteria: * Men or women 50 years of age or older * Advanced dry AMD with GA in the study eye * BCVA Snellen equivalent of 20/80 or worse in the study eye using ETDRS charts at a starting distance of 4m after the first 3 patients are enrolled and demonstrate favorable safety data * Total ...